A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-<i>CRLF2</i>-Rearranged JAK Pathway Alterations

Sarah K. Tasian, Deborah Hunter, I-Ming L. Chen, Richard C. Harvey, Andrew J. Carroll, Elizabeth M. Wagner, Shalini C. Reshmi, Michael J. Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh